Ultrasound contrast-enhanced study as an imaging biomarker for anti-cancer drug treatment: preliminary study with paclitaxel in a xenograft mouse tumor model (secondary publication).
- Author:
Hak Jong LEE
1
;
Sung Il HWANG
;
Jonghoe BYUN
;
Hoon Young KONG
;
Hyun Sook JUNG
;
Mira KANG
Author Information
- Publication Type:Original Article
- Keywords: Ultrasonography; Contrast agent; Angiogenesis; Anti-cancer treatment; Animal study
- MeSH: Animals; Area Under Curve; Follow-Up Studies; Heterografts*; Humans; Mice*; Microvessels; Paclitaxel*; Peritoneal Cavity; Prostatic Neoplasms; Tumor Burden; Ultrasonography*
- From: Ultrasonography 2017;36(4):370-377
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to assess tumor angiogenesis using contrast-enhanced ultrasonography (CEUS) of human prostate cancer cells (PC3) that were implanted in mice before and after paclitaxel injection. METHODS: Twelve mice were injected with human PC3. The mice were grouped into two groups; one was the paclitaxel-treated group (n=6) and the other was the control group (n=6). Before administering paclitaxel into the peritoneal cavity, baseline CEUS was performed after the administration of 500 μL (1×108 microbubbles) of contrast agent. The area under the curve (AUC) up to 50 seconds after injection was derived from the time-intensity curves. After injection of paclitaxel or saline, CEUS studies were performed at the 1-week follow-up. Changes in tumor volume and the AUC in both two groups were evaluated. After CEUS, the microvessel density (MVD) was compared between the groups. RESULTS: In the paclitaxel-treated group, the AUC from CEUS showed a significant decrease 1-week after paclitaxel administration (P=0.030), even though the tumor volume showed no significant changes (P=0.116). In the control group, there was no significant decrease of the AUC (P=0.173). Pathologically, there was a significant difference in MVD between both groups (P=0.002). CONCLUSION: The AUC from the time intensity curve derived from CEUS showed an early change in response to the anti-cancer drug treatment that preceded the change in tumor size. The findings of CEUS could serve as an imaging biomarker for assessing tumor responses to anti-cancer drug treatment.
